Conatus Pharmaceuticals, a San Diego-based drug developer targeting liver disease and cancer, announced it has acquired Pfizer subsidiary Idun Pharmaceuticals for an undisclosed sum. Conatus was launched in 2005 by Idun execs after Pfizer acquired the firm, which at the time was developing liver disease treatments and oncology drugs, and held intellectual property in the area of apoptosis. “Conatus plans to leverage its scientific and drug development expertise and resources to continue to advance potentially important therapeutic candidates in liver disease and oncology,” said Conatus CEO Steven Mento of the company’s acquisition of Idun.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
